Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.76 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | DLAT | P10515 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317724 | 1.00 | ALOX5 (0.76) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL819795 | 0.89 | ALOX5 (0.71) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL12327984 | 0.89 | ALOX5 (0.71) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL29888655 | 0.87 | ALOX5 (0.61) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL7897350 | 0.87 | MEN1 (0.74) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL9773779 | 0.86 | ALOX5 (1.00) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL6125220 | 0.86 | ALOX5 (1.00) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL144835 | 0.86 | ALOX5 (1.00) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL6125218 | 0.86 | ALOX5 (1.00) | ALOX5KDM4EMEN1KMT2AAKR1B10 | |
| SCHEMBL316240 | 0.86 | ALOX5 (0.56) | ALOX5KDM4EMEN1KMT2AAKR1B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275721-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2011-11-10 | — | — | US | claimed |
| US-20110257074-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2011-10-20 | — | — | US | claimed |
| EP-2364083-A1 | A METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | Metaproteomics, LLC (US) | 2011-09-14 | — | — | EP | claimed |
| WO-2010068731-A1 | A METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2010-06-17 | — | — | WO | claimed |
| US-20110275721-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275721-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110257074-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257074-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2011-10-20 | — | — | US | disclosed |
| EP-2364083-A1 | A METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | Metaproteomics, LLC (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010068731-A1 | A METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | METAPROTEOMICS, LLC (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275721-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | CYCS, CYP1B1, PDE1C | ALOX5 1912/4885KDM4E 3288/4885MEN1 4344/4885 |
| US-20110257074-A1 | METHOD FOR THE PURIFICATION OF SUBSTITUTED CYCLOPENT-2-EN-1-ONE CONGENERS AND SUBSTITUTED 1,3-CYCLOPENTADIONE CONGENERS FROM A COMPLEX MIXTURE USING COUNTERCURRENT SEPARATION | CYCS, CYP1B1, PDE1C | ALOX5 1912/4885KDM4E 3288/4885MEN1 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.